Slide 1: Nine-Month Figures 2024
Formycon AG Nine-Month Figures 2024 November 28, 2024 15:00 (CET)
Slide 2: Disclaimer
Disclaimer This presentation may contain forward-looking statements and information which are based on our current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial si
Slide 3: Maximizing our assets along a clear path
Laser focus on pipeline execution and expansion Maximizing our assets along a clear path 2023 2024 Strong financial Important year Sustainable and operational to prepare the profitability with performance ground for the continuous pipeline next ignition growth stage 3 Formycon AG — 9M 2024
Slide 4: Formycon fully on track – Highlights 2024
Biosimilar Development F O R M YC O N F U L LY O N T R A C K – HIGHLIGHTS 2024 4 Formycon AG — 9M 2024
Slide 5: Many important milestones achieved in 2024
Many important Milestones achieved in 2024 – further exciting News expected in the upcoming Weeks Positive CHMP Opinion Approval of Approval of Approval of Positive CHMP Opinion for Stelara® Biosimilar- Stelara® Biosimilar- Stelara® Biosimilar- Eylea® Biosimilar-Candidate for Eylea® Biosimilar- Cand
Slide 6: Strong FYB201 performance across the world
Strong FYB201 Performance across the world FYB201 is so far launched in 20 countries UK Marketshare: >80%* US Marketshare: >40%* FYB201 launched Further potential *Volume-based · Source: IQVIA Monthly Data R3M (rolling 3-month) Cimerli® is a registered trademark of Coherus Biosciences Inc. · Ongavia
Slide 7: Launched & late-stage projects well on track – strong newsflow ahead
Launched & late-stage Projects well on track – Strong Newsflow ahead Lucentis® Biosimilar Stelara® Biosimilar Candidate Eylea® Biosimilar Candidate [Ranibizumab] [Ustekinumab] [Aflibercept] ● Launch in Canada and Switzerland ● Settlement for Launch in Europe ● FDA Approval for FYB203/ by Teva. and C
Slide 8: 2nd wave of projects progressing well
2nd wave of Projects progressing well Keytruda® Biosimilar Candidate Undisclosed New undisclosed [Pembrolizumab] Biosimilar Candidates Biosimilar Candidate ● First patient entered Phase I ● Clones with superior stability, ● New Biosimilar Candidate in the clinical trial “Dahlia” to compare productiv
Slide 9: Financial Performance as of Sept. 30, 2024
Financial Position FINANCIAL PERFORMANCE A S O F S E P T. 3 0 , 2 0 2 4 9 Formycon AG — 9M 2024
Slide 10: Profit & Loss fully on track
Profit & Loss fully on track 9M 2024 vs. 9M 2023 – Financials within expected range In € million 9M 2024 9M 2023 Change rel. Comment • 2023 includes one-time impact FYB202 partnering € 10m, • Higher margin on FYB202 development milestones in 2023, Sales 41.1 60.2 -32% • Higher royalty income FYB201
Slide 11: Sales 9M 2024 vs. 9M 2023
Sales 9M 2024 vs. 9M 2023 17.5 m 28.8 m Development Compensation Development Compensation FYB201, FYB203 FYB201, FYB203 Sales Sales 9M 2024 9M 2023 17.6 m 41.1 29.1 m 60.2 Milestone Milestone Payments Payments FYB202 FYB202 6.0 m 2.3 m Royalties FYB201 Royalties FYB201 11 Formycon AG — 9M 2024
Slide 12: Cost of Sales 9M 2024 vs. 9M 2023
Cost of Sales 9M 2024 vs. 9M 2023 7.6 m 7.7 m FYB201 FYB201 Cost of Sales Cost of Sales 9M 2024 9M 2023 32.8 38.7 10.0 m 17.6 m FYB203 FYB203 15.2 m 13.4 m FYB202 FYB202 12 Formycon AG — 9M 2024
Slide 13: FYB201 Business Model
FYB201 Business Model − Revenue and Cash resulting from cost compensation with a small ATHOS KG Development € 6.9m single digit margin paid by Bioeq AG to Formycon Project 201 GmbH to remunerate for R&D work, YTD € 6.9m. Earn-out Compensation − Position is of decreasing relevance, as development is
Slide 14: Group asset structure as of Sept. 30, 2024 vs. Dec. 31, 2023
Group asset Structure as of Sept. 30, 2024 vs. Dec. 31, 2023 Balance Sheet total Equity Liabilities € 951.6 million € 566.0 million € 385.5 million + € 61.2 million + € 63.2 million - € 2.1 million +7% +13% -0.5% Equity Ratio Non-current assets vs. Cash & Cash Equivalents Total equity and liabilitie
Slide 15: Cash-Flows and Working Capital
Cash-Flows and Working Capital 9M 2024 In € million 9M 2024 Remarks Working Capital Sept. 30, 2024 • -17.7m EBITDA • -20.6m contract asset/trade Cash and cash equivalents 33.8 Net cash from operating -41.0 receivables/contract liabilities activities FYB202 • Remainder other WC Current receivables 46
Slide 16: Outlook 2024 – Preparing the Ground
Financial Position OUTLOOK 2024 – P R E PA R I N G T H E G R O U N D 16 Formycon AG — 9M 2024
Slide 17: 2024 Guidance confirmed
2024 Guidance confirmed 9M 2024 Revenue EBITDA Adjusted EBITDA* Working Capital ● Revenue: 4Q 2024 expected in the range of € 20m 41.1 -17.7 2.9 65.8 ● EBITDA: 4Q EBITDA expected to be € million € million € million € million “black zero” ● Adjusted EBITDA At equity result 4Q also expected Guidance R
Slide 18: Formycon – now uplisted to Prime Standard!
Formycon – now uplisted to Prime Standard! − Market Segment: Frankfurt Stock Exchange Shareholder Structure Regulated Market (Prime Standard) 24.04 % Santo Holding (Deutschland) GmbH − Uplisted to Prime Standard on Nov. 12, 2024 13.25 % Wpart GmbH, Wen.Co Invest GmbH, Peter Wendeln enables Formycon'
Slide 19: Fully focused pure-play Biosimilar Company
Fully focused pure-play Biosimilar Company WE HAVE all ingredients to WE ACT in a highly WE CREATED WE ARE entering the next successfully develop and attractive market a strong Platform with stage of the Formycon commercialize a growing track record Growth Story pipeline 19 Formycon AG — 9M 2024
Slide 20: We are happy to answer your questions
Formycon AG WE ARE HAPPY TO ANSWER YO U R Q U E S T I O N S www.formycon.com 20 Formycon AG — 3Q 2024